VQW-765 — Safety, Research, Risks & Legal Status

Not medical advice. VQW-765 is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	AQW-051; CAS 669770-29-0; development code AQW051
Category	Research Chemical
Developer	Vanda Pharmaceuticals, Inc.
CAS Number	669770-29-0
Target	Alpha-7 nicotinic acetylcholine receptor (α7-nAChR), selective partial agonist
Development Stage	Phase III ongoing (social anxiety disorder); Phase II completed (performance anxiety, 2024)
Phase II Primary Endpoint	P=0.1443 (full cohort, not significant); female subgroup P=0.034 (significant)
Phase I Tolerability	Well-tolerated up to 200 mg single dose, 75 mg/day repeated dose in healthy volunteers
US legal status	Investigational drug (United States). Not FDA-approved for any indication. Not a dietary supplement. Not approved for human use outside of clinical trials. Phase III trials are ongoing as of mid-2025. Possession and use outside of an authorized clinical trial context falls into a legal gray area; it is not scheduled, but it is not approved or commercially available.

What is VQW-765?

VQW-765 (also known by its earlier development code AQW-051) is a selective partial agonist at the alpha-7 nicotinic acetylcholine receptor (α7-nAChR), developed by Vanda Pharmaceuticals, Inc. It is under clinical investigation as an on-demand treatment for social anxiety disorder and performance anxiety. It represents one of the first agents in its class to demonstrate a detectable anxiolytic signal in a randomized human trial, though full statistical significance in the primary endpoint was not achieved in Phase II.

How it works

VQW-765 binds with high affinity to α7-nAChR, a ligand-gated ion channel found throughout the central nervous system and periphery. Upon binding, it acts as a partial agonist, stimulating calcium influx in cells expressing the human receptor while avoiding the full receptor desensitization associated with full agonism. The α7-nAChR is implicated in cholinergic modulation of limbic stress-response circuits. Preclinical work demonstrated anxiolytic-like activity across multiple rodent models and cognitive enhancement in object recognition, social recognition, and Morris water-maze tasks across a broad dose range. The drug's inverted U-shaped dose-response curve observed in human Phase II data is consistent with receptor pharmacodynamics where excessive agonism saturates and desensitizes the target.

Background & history

VQW-765 was initially characterized in preclinical studies under the code AQW-051, with foundational pharmacology published around 2014 (PubMed 25363835). Phase I trials in healthy volunteers (up to 180 subjects) were completed and demonstrated tolerability at single doses up to 200 mg and repeated doses up to 75 mg daily. Vanda Pharmaceuticals advanced the compound into a Phase II randomized controlled trial (VP-VQW-765-2201; ClinicalTrials.gov NCT04800237) in 230 adults with performance/public-speaking anxiety, assessed via the Trier Social Stress Test. Results were reported in 2022 and published in the British Journal of Psychiatry in 2024 (PubMed 40340771), making VQW-765 the subject of the first published human RCT demonstrating any anxiolytic signal from an α7-nAChR agonist class. A Phase III multicenter trial in social anxiety disorder (NCT07221578, approximately 500 subjects) was subsequently initiated and is ongoing as of the time of this writing.

What the research says

The pivotal human evidence is the Phase II RCT (n=230 adults, single 10 mg dose, TSST paradigm). The primary endpoint - anxiety reduction across the full cohort - showed a trend toward reduction that did not reach statistical significance (P=0.1443). A pre-specified subgroup analysis found that females showed a significantly greater anxiolytic response (P=0.034), and females at moderate drug exposure levels showed a stronger signal (P=0.005). No serious adverse events were reported. There were fewer treatment-emergent adverse events in the VQW-765 group (n=6) than placebo (n=13); headache was the most common event (1.7% vs 3.5%). Pharmacodynamic measures including heart rate variability suggested appropriate autonomic stress responses rather than dysregulation. The inverted U-shaped dose-response pattern in the human data is a noteworthy finding that informs ongoing Phase III dosing strategy. No cognitive impairment signals were observed. Phase III is ongoing and no results are publicly available.

Reported effects

Anxiolytic-like activity demonstrated in preclinical rodent models across multiple paradigms
Signal toward acute anxiety reduction in humans (Phase II, TSST paradigm; primary endpoint P=0.1443, not statistically significant)
Statistically significant anxiolytic response in female subgroup (Phase II, P=0.034)
Cognitive enhancement in object recognition, social recognition, and spatial learning tasks in preclinical models
Well-tolerated in Phase I and Phase II with no serious adverse events reported
Inverted U-shaped dose-response observed in human data, suggesting a narrow optimal exposure window
No clinically meaningful changes in cognition or mental status observed in human trials to date

Dosing & administration (informational)

The Phase I program evaluated single doses up to 200 mg and repeated daily doses up to 75 mg in healthy volunteers. The Phase II trial used a single 10 mg dose. The Phase II data revealed an inverted U-shaped dose-response, indicating that higher doses did not produce proportionally greater effects and may have reduced efficacy. These ranges are reported here as descriptive pharmacological context from published literature only and do not constitute a dosing protocol or recommendation. No dosing guidance should be inferred from investigational trial parameters. Consult a licensed clinician for any anxiety treatment decisions.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

No serious adverse events reported across Phase I (up to 200 mg single dose, 75 mg daily repeated) or Phase II (10 mg single dose)
Treatment-emergent adverse events were numerically less frequent in the VQW-765 arm than placebo in Phase II (6 vs. 13 events)
Headache was the most commonly reported adverse event (1.7% VQW-765 vs. 3.5% placebo in Phase II)
No observed cognitive impairment or negative mental status changes in human trials
Long-term safety data are not available; Phase III is ongoing
Safety at doses outside the tested clinical range is unknown
No human data on use in special populations (pregnancy, severe hepatic/renal impairment, pediatric), drug interactions, or chronic administration beyond Phase I durations

Drug & supplement interactions

N
o
s
y
s
t
e
m
a
t
i
c
d
r
u
g
-
d
r
u
g
i
n
t
e
r
a
c
t
i
o
n
s
t
u
d
i
e
s
h
a
v
e
b
e
e
n
p
u
b
l
i
s
h
e
d
i
n
t
h
e
p
u
b
l
i
c
d
o
m
a
i
n
a
s
o
f
a
v
a
i
l
a
b
l
e
d
a
t
a
.
A
l
p
h
a
-
7
n
A
C
h
R
m
o
d
u
l
a
t
i
o
n
c
o
u
l
d
t
h
e
o
r
e
t
i
c
a
l
l
y
i
n
t
e
r
a
c
t
w
i
t
h
o
t
h
e
r
c
h
o
l
i
n
e
r
g
i
c
a
g
e
n
t
s
(
e
.
g
.
,
a
c
e
t
y
l
c
h
o
l
i
n
e
s
t
e
r
a
s
e
i
n
h
i
b
i
t
o
r
s
,
o
t
h
e
r
n
i
c
o
t
i
n
i
c
a
g
o
n
i
s
t
s
)
,
t
h
o
u
g
h
t
h
i
s
h
a
s
n
o
t
b
e
e
n
c
h
a
r
a
c
t
e
r
i
z
e
d
i
n
p
u
b
l
i
s
h
e
d
c
l
i
n
i
c
a
l
d
a
t
a
.
N
o
i
n
t
e
r
a
c
t
i
o
n
d
a
t
a
w
i
t
h
a
n
x
i
o
l
y
t
i
c
,
a
n
t
i
d
e
p
r
e
s
s
a
n
t
,
o
r
o
t
h
e
r
C
N
S
m
e
d
i
c
a
t
i
o
n
s
a
r
e
p
u
b
l
i
c
l
y
a
v
a
i
l
a
b
l
e
.

Who should avoid it

Concurrent use with other nicotinic agonists or cholinergic agents (theoretical interaction, unstudied)
Use outside of authorized clinical trial context (no commercial supply; identity and purity of any non-trial material cannot be assured)
Use in pregnancy or lactation (no data)
Use in pediatric populations (no data)
Self-directed use to treat anxiety disorders (not approved; clinical management required)

How it is commonly combined

No human data exist on combination use of VQW-765 with any other compound. Preclinical combination data are not described in available public literature. No stacking context can be responsibly described.

Legal & regulatory. Investigational drug (United States). Not FDA-approved for any indication. Not a dietary supplement. Not approved for human use outside of clinical trials. Phase III trials are ongoing as of mid-2025. Possession and use outside of an authorized clinical trial context falls into a legal gray area; it is not scheduled, but it is not approved or commercially available.

Quality & harm reduction

Safer, legal alternative we recommend

Brainy Bunch Formula. For the same cognitive-support goal, our Brain & Focus Formula is a legal nootropic blend you can buy today.

See our recommended pick

Find VQW-765 →

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

What is VQW-765 and what is it being developed to treat?

VQW-765 is an investigational alpha-7 nicotinic acetylcholine receptor partial agonist being developed by Vanda Pharmaceuticals as a potential on-demand treatment for social anxiety disorder and performance anxiety. It is not approved for any use and is only available through clinical trials.

Did VQW-765 work in human trials?

The Phase II trial (n=230, single 10 mg dose, public-speaking anxiety paradigm) did not meet its primary endpoint in the full cohort (P=0.1443). However, a pre-specified female subgroup showed a statistically significant anxiolytic response (P=0.034), particularly at moderate exposure levels (P=0.005). Phase III trials in social anxiety disorder are ongoing; definitive efficacy data are not yet available.

What is the significance of the inverted U-shaped dose-response?

Phase II data showed that the anxiolytic effect did not increase linearly with dose - a pattern referred to as an inverted U-shape. This is a recognized pharmacodynamic property of partial agonists at α7-nAChR and has practical implications for clinical dosing: too low or too high a dose may be less effective than an intermediate exposure range. This finding appears to be informing the Phase III dose selection.

Is VQW-765 safe?

In Phase I and Phase II, VQW-765 was well-tolerated. No serious adverse events were reported. In Phase II, adverse events were numerically less frequent in the drug group than in the placebo group. Long-term safety, safety in special populations, and drug interaction profiles have not been characterized in public data. Trials are still ongoing.

Can I obtain or use VQW-765?

No legitimate consumer supply exists. VQW-765 is an investigational drug manufactured for clinical trials only. It is not FDA-approved, not commercially available, and not a supplement. Any substance offered for sale as VQW-765 outside of a licensed trial cannot be verified and carries unknown risks.

What is the recommended dose of VQW-765?

There is no approved or recommended dosing regimen. The clinical trials have explored specific doses in controlled research settings. That information exists in the scientific literature for research literacy purposes only and should not be interpreted as a protocol. Anyone seeking treatment for anxiety disorders should consult a licensed clinician.

References & further reading

PubMed 40340771 - Phase II RCT: efficacy and safety of VQW-765 in performance anxiety (British Journal of Psychiatry, 2024)
PubMed 25363835 - AQW051 preclinical characterization: potent selective alpha-7 nAChR partial agonist, Phase I data
ClinicalTrials.gov NCT04800237 - Phase II performance anxiety trial (VP-VQW-765-2201)
ClinicalTrials.gov NCT07221578 - Phase III social anxiety disorder trial (ongoing)
PubMed search: alpha-7 nicotinic acetylcholine receptor anxiolytic partial agonist clinical trial